Compare Stocks → At first glance, this chart looks like nonsense… (From The TradingPub) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AIMTNASDAQ:ALDRNASDAQ:APLSNASDAQ:EIDXNASDAQ:TCDA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMTAimmune Therapeutics$34.49$34.46$10.09▼$37.00$2.26B1.761.71 million shsN/AALDRAlder Biopharmaceuticals$18.88$18.88$8.39▼$19.12$1.58B2.645.12 million shsN/AAPLSApellis Pharmaceuticals$49.75+2.1%$58.96$19.83▼$94.75$6.00B0.881.48 million shs697,785 shsEIDXEidos Therapeutics$122.21$123.21$28.39▼$132.54$4.75B-0.16128,113 shsN/ATCDATricida$0.13$0.09▼$13.85$6.01M0.2217.62 million shs31.13 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMTAimmune Therapeutics0.00%0.00%0.00%0.00%0.00%ALDRAlder Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%APLSApellis Pharmaceuticals+2.27%-5.98%-12.04%-26.76%-45.12%EIDXEidos Therapeutics0.00%0.00%0.00%0.00%0.00%TCDATricida0.00%0.00%0.00%0.00%0.00%One trade. One ticker. One week. (Ad)Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? Well, then you should click here to see this free training.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMTAimmune TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AALDRAlder BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAPLSApellis Pharmaceuticals4.4432 of 5 stars4.42.00.04.41.82.50.6EIDXEidos TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATCDATricidaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMTAimmune TherapeuticsN/AN/AN/AN/AALDRAlder BiopharmaceuticalsN/AN/AN/AN/AAPLSApellis Pharmaceuticals2.87Moderate Buy$77.9356.65% UpsideEIDXEidos TherapeuticsN/AN/AN/AN/ATCDATricidaN/AN/AN/AN/ACurrent Analyst RatingsLatest AIMT, TCDA, EIDX, APLS, and ALDR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2024APLSApellis PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$67.00 ➝ $57.004/15/2024APLSApellis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$92.004/9/2024APLSApellis PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$85.003/27/2024APLSApellis PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$60.003/6/2024APLSApellis PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$78.00 ➝ $79.003/4/2024APLSApellis PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$87.00 ➝ $89.002/28/2024APLSApellis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$92.002/28/2024APLSApellis PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$60.00 ➝ $67.002/16/2024APLSApellis PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$49.00 ➝ $60.002/6/2024APLSApellis PharmaceuticalsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$81.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMTAimmune TherapeuticsN/AN/AN/AN/A$1.66 per shareN/AALDRAlder Biopharmaceuticals$1.62M977.10N/AN/A$1.61 per share11.73APLSApellis Pharmaceuticals$396.59M15.13N/AN/A$1.64 per share30.34EIDXEidos Therapeutics$26.69M177.99N/AN/A$4.57 per share26.74TCDATricidaN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMTAimmune Therapeutics-$248.50M-$3.97N/AN/AN/AN/A-164.99%-89.50%N/AALDRAlder Biopharmaceuticals-$296.43M-$4.87N/AN/AN/AN/A-226.13%-66.86%N/AAPLSApellis Pharmaceuticals-$528.63M-$4.48N/A46.06N/A-133.34%-178.60%-60.41%5/7/2024 (Confirmed)EIDXEidos Therapeutics-$37.83M-$1.03N/AN/AN/AN/A-65.21%-53.04%N/ATCDATricida-$176.57M-$2.36N/AN/AN/AN/AN/A-103.81%N/ALatest AIMT, TCDA, EIDX, APLS, and ALDR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2024N/AAPLSApellis Pharmaceuticals-$0.55N/A+$0.55N/AN/AN/A 2/27/202412/31/2023APLSApellis Pharmaceuticals-$0.73-$0.73N/A-$0.73$143.34 million$146.38 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMTAimmune TherapeuticsN/AN/AN/AN/AN/AALDRAlder BiopharmaceuticalsN/AN/AN/AN/AN/AAPLSApellis PharmaceuticalsN/AN/AN/AN/AN/AEIDXEidos TherapeuticsN/AN/AN/AN/AN/ATCDATricidaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMTAimmune Therapeutics0.737.537.40ALDRAlder Biopharmaceuticals1.748.948.94APLSApellis Pharmaceuticals0.483.102.50EIDXEidos Therapeutics0.1411.1011.10TCDATricidaN/A4.874.87OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMTAimmune Therapeutics74.47%ALDRAlder BiopharmaceuticalsN/AAPLSApellis Pharmaceuticals96.29%EIDXEidos Therapeutics31.40%TCDATricidaN/AInsider OwnershipCompanyInsider OwnershipAIMTAimmune Therapeutics13.75%ALDRAlder Biopharmaceuticals15.40%APLSApellis Pharmaceuticals7.50%EIDXEidos Therapeutics70.10%TCDATricida35.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAIMTAimmune Therapeutics22865.45 millionN/AOptionableALDRAlder Biopharmaceuticals20283.84 millionN/AOptionableAPLSApellis Pharmaceuticals702120.58 million111.54 millionOptionableEIDXEidos Therapeutics7038.87 millionN/ANot OptionableTCDATricida5755.67 million35.85 millionNot OptionableAIMT, TCDA, EIDX, APLS, and ALDR HeadlinesSourceHeadlineSierraConstellation Partners Receives Industry Recognition for Work with Tricidafinance.yahoo.com - February 6 at 10:02 AMTricida Inc (TCDAQ)es.investing.com - January 13 at 10:29 AMEmerging Therapies in the Treatment of Clostridium difficile-Associated Diseasemedscape.com - May 30 at 8:27 AMVaniam Group Hires Paula Franson to Lead Clinical Strategy & Solutions - Yahoo Financenews.google.com - April 18 at 12:45 AMMetabolic Acidosis Market to Witness Growth by 2032, Estimates ... - Digital Journalnews.google.com - April 17 at 7:44 PMReal-time PCR as a Diagnostic Tool for Bacterial Diseasesmedscape.com - April 12 at 11:47 PMChronic Kidney Disease Drugs Market Expected To Propel Market ... - Digital Journalnews.google.com - April 10 at 8:38 AMChronic Kidney Disease Drugs Market Huge Growth in Future ... - Digital Journalnews.google.com - April 6 at 7:54 AMTricida Heading For Ch. 11 Confirmation Fight With Creditors - Law360news.google.com - March 24 at 11:19 PMAlicia Dixon Joins COPILOT Provider Support Services as VP of Strategy Development & Execution - Yahoo Financenews.google.com - March 14 at 3:50 PMAlicia Dixon Joins COPILOT Provider Support Services as VP of ... - Yahoo Financenews.google.com - March 14 at 10:49 AMTricida Heads To Ch. 11 Mediation Over Creditor Plan Issues - Law360news.google.com - March 6 at 10:59 PMTroubled Adamis To Merge With Private DMK, Focus On ... - Scripnews.google.com - March 1 at 12:17 PMRelease Opt Out Trips Up Tricida Ch. 11 Disclosure Approval - Law360news.google.com - February 27 at 8:43 PMRenibus Buys Tricida's Kidney Drug Veverimer In Ch. 11 Sale - Law360news.google.com - February 21 at 8:22 PMSTONEHILL CAPITAL MANAGEMENT LLC Buys 2, Sells 3 in 4th ... - GuruFocus.comnews.google.com - February 18 at 1:53 AMTop 5 4th Quarter Trades of ORBIMED ADVISORS LLC - GuruFocus.comnews.google.com - February 18 at 1:53 AMTricida, Inc. (TCDA) Stock Historical Prices & Data - Yahoo Financefinance.yahoo.com - February 14 at 7:22 PMRising Serum Bicarbonate Lowers CKD Progression Risk in ... - Renal and Urology Newsnews.google.com - February 8 at 7:43 AMFirm Retention Summary: Tricida Inc.wsj.com - February 3 at 3:38 PMTricida's Chapter 11 Liquidation – Global Legal Chronicle - Global Legal Chroniclenews.google.com - January 29 at 8:47 AMTricida Gets OK To Seek Stalking Horse For Ch. 11 Auction - Law360news.google.com - January 26 at 6:43 PMWeak Fundamental Momentum Drags Tricida Inc. (TCDA) Lower - Marketing Sentinelnews.google.com - January 24 at 2:09 PMTricida Inc. (TCDA): This Stock is set to Soar Above its Peers - Invest Chroniclenews.google.com - January 24 at 9:08 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAimmune TherapeuticsNASDAQ:AIMTAimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.Alder BiopharmaceuticalsNASDAQ:ALDRAlder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.Apellis PharmaceuticalsNASDAQ:APLSApellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Eidos TherapeuticsNASDAQ:EIDXEidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.TricidaNASDAQ:TCDATricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.